P.S. Free & New ALS-Con-201 dumps are available on Google Drive shared by DumpsKing: https://drive.google.com/open?id=1BvnRqo0k-UOWqVar4F4jVRbftzCXvoh_
ALS-Con-201 pdf file is the most favorite readable format that many candidates prefer to. You can download and install ALS-Con-201 pdf torrents on your PC or phone. If you are tired of the way to study, you can also print ALS-Con-201 pdf dumps into papers which can allow you to do marks as you like. As we all know, the ALS-Con-201 study notes on the papers are easier to remember. Whatβs more, we use Paypal which is the largest and reliable platform to deal the payment, keeping the interest for all of you.
| Certification Vendor: | Salesforce |
|---|---|
| Exam Name: | Salesforce Certified Agentforce Life Sciences Consultant |
| Exam Number: | ALS-Con-201 |
| Exam Price: | US$200 |
| Real Exam Qty: | 60-65 |
| Related Certifications: | Salesforce Certified Platform Administrator |
| Passing Score: | 62% |
| Exam Format: | Multiple-choice, Scenario-based |
| Exam Duration: | 105 minutes |
| Certificate Validity Period: | 2 years |
| Available Languages: | English |
| Recommended Training: | Agentforce Life Sciences Consultant Certification Preparation |
| Exam Registration: | Salesforce Certification Registration |
| Sample Questions: | Salesforce ALS-Con-201 Sample Questions |
| Exam Way: | Online proctored or onsite testing center |
| Pre Condition: | Hold Salesforce Certified Platform Administrator certification; at least 1 year experience in life sciences industry; at least 6 months hands-on experience configuring Agentforce Life Sciences |
| Official Syllabus URL: | https://help.salesforce.com/s/articleView?id=005305357&language=en_US |
>> ALS-Con-201 Latest Learning Materials <<
As you see, all of the three versions of our ALS-Con-201 exam dumps are helpful for you to get the ALS-Con-201 certification. So there is another choice for you to purchase the comprehensive version which contains all the three formats. And no matter which format of ALS-Con-201 study engine you choose, we will give you 24/7 online service and one year's free updates. Moreover, we can assure you a 99% percent pass rate.
| Topic | Details |
|---|---|
| Topic 1 |
|
| Topic 2 |
|
| Topic 3 |
|
| Topic 4 |
|
NEW QUESTION # 17
Choose 1 option.
Cumulus Pharma has a compliance policy regarding "Off-Label" discussions. The company's Agentforce Life Sciences Consultant needs to configure the Agentforce Life Sciences visit experience to explicitly control whether field sales reps are allowed to discuss products for indications that have not yet been approved.
Which setting within the Admin Console handles this capability?
Answer: C
Explanation:
The correct answer is B because off-label control in the visit experience is tied to product detailing behavior. In life sciences commercial engagement, product detailing governs what products, messages, indications, and approved content can be discussed or shown during a visit. Salesforce Trailhead describes Life Sciences Cloud content visibility as being filtered by territory, product assignment, and account restrictions to prevent off-label or noncompliant sharing. This aligns most closely with Visit Settings > Product Detailing Settings, because that is the visit configuration area where product discussion and detailing behavior is controlled.
The question asks where the consultant should configure whether reps are allowed to discuss products for unapproved indications. That is not a generic compliance switch; it is a visit-detailing control connected to product and indication behavior in the field engagement workflow. Product Detailing Settings are therefore the correct place to enforce whether off-label discussion is permitted, warned, or restricted according to company policy.
Option A is incorrect because "Compliance Settings > Off-Label Validation" is not the standard configuration path presented in the available options for the Life Sciences visit experience. Option C is also incorrect because Restricted Products would control whether products are available or restricted, but the scenario is specifically about discussion of unapproved indications during product detailing. Therefore, the consultant should use Visit Settings > Product Detailing Settings.
=========
NEW QUESTION # 18
Choose 1 option.
Cumulus Pharma wants to use an external third-party provider to deliver emails sent from the Agentforce Life Sciences mobile app, rather than using the standard Salesforce email limits.
Which Apex interface should an Agentforce Life Sciences Consultant implement to manage the handoff of email operations to this third-party provider?
Answer: A
Explanation:
The correct answer is C because Salesforce Life Sciences Cloud provides the Lsc4ce.EmailQueueProcessor interface for using a third-party email service. Salesforce Help for using a third-party email service states that administrators should create a global Apex class that implements the Lsc4ce.EmailQueueProcessor interface. This interface is the supported extension point for handing off Life Sciences email operations to an external email provider instead of relying only on Salesforce's standard email sending behavior and limits.
This scenario is specifically about emails sent from the Agentforce Life Sciences mobile app. Salesforce's Field Email capability is designed to streamline compliant email creation, sending, and tracking for Life Sciences users, and the developer documentation describes LifeScienceEmail as representing a collection of sendable messages that manages creation, sending, and tracking of email communications. When an organization needs an external provider to send those emails, the custom Apex implementation must process the queued email operation and pass it to the third-party service.
Option A is incorrect because Lsc4ce.ExternalEmailHandler is not the interface identified by Salesforce for third-party email service handoff. Option B is also incorrect because Lsc4ce.MessagingService is not the documented Life Sciences email queue processing interface. Therefore, the consultant should implement Lsc4ce.EmailQueueProcessor.
=========
NEW QUESTION # 19
Choose 1 option.
When a field sales rep delivers samples they have physically received but have not yet acknowledged in the system, a Product Disbursement record is created with a warning. The system must maintain inventory integrity.
Which action is required to reconcile the product sample count?
Answer: B
Explanation:
The correct answer is A because Salesforce Life Sciences Sample Inventory Management includes a process for fixing unresolved product disbursements. Salesforce Help for managing samples references Fix Unresolved Product Disbursements, and the same Sample Inventory Management area describes inventory operations such as transfers, returns, shipments, assigned batches, and product disbursements as part of the sample lifecycle.
The issue occurs because the rep physically received samples and handed them to an HCP before formally acknowledging the inventory in the system. To preserve inventory integrity, Salesforce cannot simply reduce inventory counts as if the stock were already confirmed in the rep's available inventory. Instead, the system flags the Product Disbursement as unresolved. The rep must first acknowledge the inventory so the system recognizes the received stock, and then use the Resolve Disbursement quick action to complete the reconciliation and finalize the inventory count updates.
Option B is incorrect because the process does not require an admin to manually override an unresolved status in org-wide settings. This is an operational correction handled by the rep through the sample inventory workflow. Option C is also incorrect because forcing a Manual Adjustment would bypass the intended reconciliation process and could weaken auditability. The proper Life Sciences process is to acknowledge the inventory and then resolve the disbursement using the quick action.
=========
NEW QUESTION # 20
Choose 1 option.
Cumulus Pharma uses Agentforce Account Summary to provide the latest and most relevant account information before each Healthcare Provider (HCP) interaction. The company is onboarding a new persona for its Key Account Managers (KAMs). Provider account summaries generated for this new persona need information from two additional custom objects that store insights and market intelligence.
Which configuration ensures the new information is used only while generating the provider summary for this new persona?
Answer: B
Explanation:
Option A is correct because Account Summarization uses cross-object graphs to determine which related objects and relationships are included in generated summaries. Salesforce Life Sciences Account Summarization setup resources reference creating a cross-object graph for Account Summarization and assigning cross-object graphs to an org or profile. This supports persona-specific summary behavior because a graph can be configured with the additional custom objects and then assigned specifically to the KAM profile.
The requirement says the new information must be used only for the new KAM persona. That means the consultant should avoid changing the default or shared provider summary mapping used by other personas. By creating a separate cross-object graph from the template, adding the two custom insight and market-intelligence objects, and assigning that graph only to the KAM profile, the consultant isolates the new summary structure to the intended users.
Option B is not the best answer because globally updating Provider Summary Objects mapping could affect more than the KAM persona if the mapping is shared. Option C is also not the best answer because the key Account Summarization configuration pattern documented by Salesforce is graph creation and graph assignment to an org or profile. Therefore, the correct configuration is to create a new cross-object graph and assign it to the KAM profile.
=========
NEW QUESTION # 21
Choose 1 option.
Cumulus Pharma uses standard Salesforce dashboards to help field sales reps track basic activities, such as visits and engagement trends. After customizing a dashboard and adding it to the home page, the reps report that funnel charts are not visible when viewing the dashboard in the Agentforce Life Sciences mobile app, even though they appear on desktop.
What should an Agentforce Life Sciences Consultant recommend?
Answer: A
Explanation:
Option A is correct because this is a mobile rendering limitation, not a data or filter issue. Salesforce documentation for reports and dashboards on mobile describes differences and limitations between desktop and the Salesforce mobile app. When a dashboard component appears on desktop but not in the mobile app, the consultant should first check mobile dashboard support and component compatibility rather than assuming that the report data is missing.
The question states that the funnel charts appear on desktop, which strongly indicates that the underlying reports and reporting periods are valid. If the data were missing for the selected reporting period, the chart would fail or show no data consistently, not only on mobile. Option C is therefore not a good fit. Option B is also incorrect because dashboard filters can affect what data is shown, but they do not make an unsupported chart type render in the mobile app.
Salesforce Help also discusses making dashboards available in mobile workflows and notes that mobile dashboard behavior depends on how dashboards are embedded and rendered in the Salesforce mobile app. For this scenario, the consultant should recommend replacing the funnel chart with a mobile-supported visualization or providing an alternate dashboard component for mobile users. Therefore, the correct answer is that funnel charts are not supported in the mobile app.
NEW QUESTION # 22
......
Latest ALS-Con-201 Exam Questions: https://www.dumpsking.com/ALS-Con-201-testking-dumps.html
P.S. Free 2026 Salesforce ALS-Con-201 dumps are available on Google Drive shared by DumpsKing: https://drive.google.com/open?id=1BvnRqo0k-UOWqVar4F4jVRbftzCXvoh_